La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
PAVmed Gestione
Gestione criteri di controllo 2/4
PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 10.17 years. total yearly compensation is $953.20K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 3.61% of the company’s shares, worth $255.19K. The average tenure of the management team and the board of directors is 1.9 years and 9.6 years respectively.
Informazioni chiave
Lishan Aklog
Amministratore delegato
US$953.2k
Compenso totale
| Percentuale dello stipendio del CEO | 95.8% |
| Mandato del CEO | 10.2yrs |
| Proprietà del CEO | 3.6% |
| Durata media del management | 1.9yrs |
| Durata media del Consiglio di amministrazione | 9.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed: A True Game-Changer For Medical Device Innovation
Jun 14PAVmed forms digital health company, Veris Health
Jun 02PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device
May 26PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19PAVmed drops 14% on launch of $13.4M direct offering
Jan 06PAVmed closes additional direct offering of common stock
Dec 22Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16PAVmed offers stock for $8.9M
Dec 11PAVmed EPS beats by $0.02
Nov 17There Is Progress At PAVmed, But More Patience Is Required
Oct 30Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$953k | US$913k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$79m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$1m | US$901k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$58m |
| Dec 31 2021 | US$9m | US$583k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$1m | US$431k | -US$35m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$890k | US$431k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$772k | US$346k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$444k | US$297k | -US$10m |
Compensazione vs Mercato: Lishan's total compensation ($USD953.20K) is above average for companies of similar size in the US market ($USD680.04K).
Compensazione vs guadagni: Lishan's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Lishan Aklog (58 yo)
10.2yrs
Mandato
US$953,200
Compensazione
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 10.2yrs | US$953.20k | 3.61% $ 255.2k | |
| President & CFO | 7.4yrs | US$673.50k | 0.49% $ 34.5k | |
| Executive VP & COO | 2.5yrs | US$498.00k | 0.17% $ 12.2k | |
| Executive VP | 2.3yrs | US$710.50k | 0% $ 0 | |
| Executive VP | 1.3yrs | US$593.10k | 0% $ 0 | |
| Senior VP of Molecular Genetics & Chief Scientific Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP | 1.6yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Medical Officer | 1.6yrs | Nessun dato | Nessun dato |
1.9yrs
Durata media
58yo
Età media
Gestione esperta: PAVM's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & CEO | 10.2yrs | US$953.20k | 3.61% $ 255.2k | |
| Independent Director | 9.6yrs | US$251.90k | 0.62% $ 44.1k | |
| Member of Medical Advisory Board | 9.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.2yrs | US$238.90k | 0.62% $ 44.1k | |
| Independent Director | 9.6yrs | US$228.90k | 0.62% $ 44.1k | |
| Member of Medical Advisory Board | 9.8yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 9.6yrs | Nessun dato | Nessun dato | |
| Independent Vice Chairman | 9.8yrs | US$228.90k | 0.78% $ 55.5k | |
| Member of Medical Advisory Board | 9.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.3yrs | US$248.90k | 0.62% $ 44.1k | |
| Member of Medical Advisory Board | 7.8yrs | Nessun dato | Nessun dato |
9.6yrs
Durata media
62.5yo
Età media
Consiglio di amministrazione esperto: PAVM's board of directors are considered experienced (9.6 years average tenure).